Beau Nakamoto to Anti-HIV Agents
This is a "connection" page, showing publications Beau Nakamoto has written about Anti-HIV Agents.
Connection Strength
1.098
-
Nakamoto BK, Shikuma CM, Ogata-Arakaki D, Umaki T, Neuwelt EA, Shiramizu BT, Chow DC, Parikh NI, Kallianpur KJ, Hamilton BE. Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder. J Neurovirol. 2013 Dec; 19(6):601-5.
Score: 0.340
-
Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B, Chow DC, Kallianpur K, Shikuma CM. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):759-65.
Score: 0.271
-
D'Antoni ML, Paul RH, Mitchell BI, Kohorn L, Fischer L, Lefebvre E, Seyedkazemi S, Nakamoto BK, Walker M, Kallianpur KJ, Ogata-Arakaki D, Ndhlovu LC, Shikuma C. Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism. J Acquir Immune Defic Syndr. 2018 09 01; 79(1):108-116.
Score: 0.119
-
Zungsontiporn N, Ndhlovu LC, Mitchell BI, Stein JH, Kallianpur KJ, Nakamoto B, Keating SM, Norris PJ, Souza SA, Shikuma CM, Chow DC. Serum amyloid P (SAP) is associated with impaired brachial artery flow-mediated dilation in chronically HIV-1 infected adults on stable antiretroviral therapy. HIV Clin Trials. 2015 11; 16(6):228-35.
Score: 0.098
-
Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014 Dec; 20(6):571-82.
Score: 0.091
-
Nakamoto BK, Jahanshad N, McMurtray A, Kallianpur KJ, Chow DC, Valcour VG, Paul RH, Marotz L, Thompson PM, Shikuma CM. Cerebrovascular risk factors and brain microstructural abnormalities on diffusion tensor images in HIV-infected individuals. J Neurovirol. 2012 Aug; 18(4):303-12.
Score: 0.077
-
Premeaux TA, D'Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto BK, Agsalda-Garcia M, Shiramizu B, Shikuma CM, Gissl?n M, Price RW, Valcour V, Ndhlovu LC. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019 04; 25(2):150-161.
Score: 0.030
-
Shikuma CM, Kohorn L, Paul R, Chow DC, Kallianpur KJ, Walker M, Souza S, Gangcuangco LMA, Nakamoto BK, Pien FD, Duerler T, Castro L, Nagamine L, Soll B. Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy. HIV Clin Trials. 2018 08; 19(4):139-147.
Score: 0.030
-
Tongma C, Shikuma CM, Nakamoto BK, Kallianpur KJ, Umaki TM, Barbour JD, Ndhlovu L, Parikh NI, Chow DC. Albuminuria as a marker of cardiovascular risk in HIV-infected individuals receiving stable antiretroviral therapy. Hawaii J Med Public Health. 2013 Sep; 72(9 Suppl 4):34-8.
Score: 0.021
-
Gangcuangco LM, Chow DC, Liang CY, Nakamoto BK, Umaki TM, Kallianpur KJ, Shikuma CM. Predictors of 25-hydroxyvitamin D levels in HIV-infected patients in Hawai'i. Hawaii J Med Public Health. 2013 Jun; 72(6):197-201.
Score: 0.021